This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas

This study has been terminated.
(IND was withdrawn by CTEP due to low accrual and cost of maintaining the IND.)
Sponsor:
Information provided by (Responsible Party):
Wyndham Wilson, M.D., National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00082017
First received: April 28, 2004
Last updated: May 1, 2017
Last verified: May 2017
April 28, 2004
May 1, 2017
April 5, 2004
September 27, 2011   (Final data collection date for primary outcome measure)
  • Clinical Response Rate [ Time Frame: 74.5 months ]
    Clinical Response Rate is the percentage of participants with a response assessed by the International Workshop to Standardize Response Criteria. Complete response (CR) is complete disappearance of all detectable clinical and radiographic evidence of disease. Complete response unconfirmed (CRu) is per CR criteria except that if a residual node is >1.5cm, it must have regressed by >75%. Partial response (PR) is no increase in size of nodes, liver or spleen. Progressive disease (PD) is a greater than or equal to 50% increase from nadir. Details re: response criteria, see the protocol link module
  • Progression Free Survival (PFS) [ Time Frame: 3.6 months ]
    PFS is defined as the time interval from start of treatment to documented evidence of disease progression. Disease progression is assessed by the International Workshop to Standardize Response Criteria for non-Hodgkin's Lymphomas and is defined as a ≥50% increase from nadir in the sum of the products of the greatest diameters of any previously identified abnormal node for partial response's or non-responders or appearance of any new lesion during or at the end of therapy.
  • Overall Survival (OS) [ Time Frame: 55 months ]
    OS is defined as the date of on-study to the date of death from any cause or last follow up.
Not Provided
Complete list of historical versions of study NCT00082017 on ClinicalTrials.gov Archive Site
Number of Participants With Adverse Events [ Time Frame: 76 months ]
Here is the number of participants with adverse events. For a detailed list of adverse events, see the adverse event module.
Not Provided
  • Effect of UCN-01 on Soluble TAC Cluster of Differentiation 25 (CD25) [ Time Frame: Day 3-5 after drug administration ]
    Soluble TAC (CD25) levels will be assessed in patients with anaplastic large cell lymphoma.
  • Evaluation of Mature T-cell Lymphoma Cells by Complementary Double-Stranded Deoxyribonucleic Acid (cDNA) Microarray [ Time Frame: Day 3-5 after drug administration ]
    Mature T-cells will be analyzed to identify gene expression changes that correlate with loss of a tumor suppressor gene in a human melanoma cell line.
  • Effect of UCN-01 on Anaplastic Lymphoma Kinase (ALK) Expression in ALCL [ Time Frame: Day 3-5 after drug administration ]
    Gene expression patterns in participants ALK positive tumors will be assessed.
Not Provided
 
UCN-01 (7-Hydroxystaurosporine) to Treat Relapsed T-Cell Lymphomas
Phase II Study of UCN-01 in Relapsed or Refractory Systemic Anaplastic Large Cell and Mature T-Cell Lymphomas

This study will examine the effects of an experimental drug called UCN-01 (7-hydroxystaurosporine) on T-cell lymphomas. UCN-01 inhibits the growth of several different tumor cells, and, in laboratory studies, it has worked particularly well on tumor cells taken from patients with T cell lymphomas.

Patients 9 years of age and older with T cell lymphoma that has relapsed or is not responding to chemotherapy may be eligible for this study. Candidates will be screened with a medical histories and physical examinations, blood and urine tests, electrocardiograms, chest x-rays, and computed tomography (CT) scans of the chest, abdomen and pelvis. Additional tests may be done if clinically indicated, such as positron emission tomography (PET) scans, bone marrow aspirations and biopsies, lumbar punctures (spinal taps) and CT's or magnetic resonance imaging (MRI) scans if there is evidence of central nervous system disease.

Participants are given UCN-01 in 28-day treatment cycles. The drug is given by vein in a continuous 72-hour infusion on the first cycle and in 36-hour infusions on subsequent cycles. The total number of cycles patients receive depends on how well the tumor responds to the drug and how well the patient tolerates drug side effects. Patients who do well may receive treatment for up to 1 year. Patients whose disease worsens with treatment or who do not tolerate the therapy are taken off the study.

Some or all of the screening tests are repeated periodically during the course of treatment to monitor safety and treatment response. X-rays and scans are done every other treatment cycle for the first 6 cycles and then, if the cancer is stable or improving, the interval between these imaging studies is lengthened to every 4 cycles. Patients whose tumors can be safely biopsied undergo this procedure before entering the study and 3 to 5 days after completing the first UCN-01 treatment. Biopsies requiring open surgery (e.g., in the chest or abdomen) are done only if absolutely necessary for medical care. Biopsy tissue, blood, and other fluids are analyzed for gene and protein studies related to lymphoma research.

Background:

  • UCN-01 (7-hydroxystaurosporine), a non-specific protein kinase C (PKC) inhibitor appears to have several mechanisms of action including protein kinase C (PKC) isoenzyme inhibition and cyclin dependent kinase activation and inhibition.
  • We have demonstrated that cell lines derived from T-cell lymphomas, including those with the t (2; 5) translocation, are very sensitive to UCN-01. The t (2; 5) translocation, associated with three quarters of cases of anaplastic large cell lymphomas (ALCL), is an oncogenic fusion protein - nucleophosmin-anaplastic lymphoma kinase (NPM-ALK).
  • Anaplastic lymphoma receptor tyrosine kinase (ALK) is one potential target for UCN-01 action, and anaplastic large cell lymphoma (ALCL) derived SUDHL-1 cells containing the NPM-ALK protein have been shown to be very sensitive to UCN-01.

Objectives:

  • To assess the clinical response to UCN-01 and progression-free and overall survival in patients with relapsed or refractory systemic Anaplastic Large Cell and other mature T-cell Lymphomas.
  • To assess the effect of UCN-01 on ALK expression in ALCL cells.
  • To assess the effect of UCN-01 on soluble tetrameric antibody complexes (TAC) (CD25).
  • To evaluate mature T-cell lymphoma malignant cells by complimentary deoxyribonucleic acid (cDNA) microarray.

Eligibility:

  • Relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL) with T or Null phenotype or relapsed or refractory mature T-cell lymphomas.
  • All patients should have evaluable or measurable disease on entry to study.
  • Requires systemic therapy
  • Performance Status Eastern Cooperative Oncology Group (ECOG) less than or equal to 2
  • Age 7 years or older
  • Human immunodeficiency virus (HIV) negative
  • Patients should not have received systemic cytotoxic chemotherapy within 3 weeks of study entry.

Design:

  • The study will be a Phase II study.
  • Patients will receive the first cycle of UCN-01 over 72 hours on days 1-3 and subsequent cycles over 36 hours. Patients with stable disease may receive UCN-01 for up to 1 year beyond achieving maximum response or stable disease, and restaging will be done every 2 cycles for the first 6 cycles and every 4 cycles thereafter.
  • Two sequential biopsies will be performed to investigate complimentary deoxyribonucleic acid (cDNA) expression by microarray. Soluble Tac (CD25) will be serially followed in patients.
  • For each of the two histologies, this study will be conducted using a Simon two-stage optimal design. Up to 37 patients will be treated.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: No masking
Primary Purpose: Treatment
  • Lymphoma, Large-Cell, Ki-1
  • Lymphoma, T-Cell
Drug: UCN-01 (7-hydroxystaurosporine)

UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.

UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days.

Other Name: UCN-01
  • Experimental: UCN-01 for T-cell lymphomas - Cohort 1 - Every 28 days

    Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2

    Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.

    Intervention: Drug: UCN-01 (7-hydroxystaurosporine)
  • Experimental: UCN-01 for T-cell lymphomas - Cohort 2 -Every 21 days

    Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2

    Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days.

    Intervention: Drug: UCN-01 (7-hydroxystaurosporine)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
20
September 27, 2011
September 27, 2011   (Final data collection date for primary outcome measure)
  • INCLUSION CRITERIA:

Relapsed or refractory systemic Anaplastic Large Cell Lymphoma (ALCL).

Relapsed or refractory mature T-cell lymphoma to include peripheral T-cell lymphoma unspecified and the following "specified" mature T-cell lymphomas:

Adult T-cell lymphoma; Extranodal natural killer (NK)/T-cell lymphoma,

nasal type; Enteropathy-type T-cell lymphoma;

Hepatosplenic T-cell lymphoma;

Subcutaneous panniculitis-like T-cell lymphoma;

Angioimmunoblastic T-cell lymphoma.

All patients should have evaluable or measurable disease on entry to study.

Histology confirmed by Laboratory of Pathology, National Cancer Institute (NCI).

Performance Status Eastern Cooperative Oncology Group (ECOG) less than or equal to 2.

Age 7 years or older.

Creatinine less than or equal to 1.5 mg/dl or creatinine clearance greater than 50 ml/min for patients at least 18 years.

Pediatric patients should have maximum serum creatinine by age as follows:

  • Less than age 7 and less than or equal to age 10 may have a Maximum Serum Creatinine of 1.0 mg/dl
  • Less than age10 and less than or equal to age 15 may have a Maximum Serum Creatinine of 1.2 mg/dl
  • Age 15 years or older may have a Maximum Serum Creatinine of 1.5 mg/dl

Alternatively, pediatric patients should have a creatinine clearance of greater than 50 m1/min/1.73m^2.

Total bilirubin less than 1.5 x upper limit of normal (ULN) (patients with elevation of total bilirubin consistent with Gilbert's disease are eligible providing they have a normal direct bilirubin);

aspartate aminotransferase (AST) less than or equal to 2.5 x ULN;

absolute neutrophil count (ANC) greater than 500/mm^3;

and platelet greater than or equal to 50,000/mm^3;

unless hematological impairment due to organ involvement by lymphoma.

Provides signed informed consent.

Not pregnant or nursing. This drug has unknown effects in pregnancy and on young infants/children.

Human immunodeficiency virus (HIV) negative.

Willing to use contraception and continue for at least 8 weeks following the last treatment.

No active central nervous system (CNS) lymphoma.

Patients should not have received systemic cytotoxic chemotherapy within 3 weeks of study entry.

Have recovered from the toxic effects of prior therapy to a grade less than or equal to 1.

No history of diabetes mellitus requiring insulin treatment.

No symptomatic pulmonary disease.

No evidence of symptomatic cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, exertional angina pectoris, cardiac arrhythmia).

Patients may not be concurrently receiving any other investigational agents.

Not a candidate for potentially curative (i.e. transplant) treatment at the time of study entry or the patient has a window of opportunity to receive UCN-01 before a transplant. Patients are required to have considered a transplant. If, having done this, they refuse it, decide against it or decide to wait, they would be eligible for this study.

Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00082017
040173
04-C-0173
No
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
No
Not Provided
Wyndham Wilson, M.D., National Cancer Institute (NCI)
National Cancer Institute (NCI)
Not Provided
Principal Investigator: Wyndham Wilson, M.D. National Cancer Institute, National Institutes of Health
National Institutes of Health Clinical Center (CC)
May 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP